SLC5A2 and atrial fibrillation: The potential relationship between sodium-glucose cotransporter-2 (SGLT-2) inhibitors and atrial fibrillation (AF) arises from the diverse and pleiotropic mechanisms of these drugs beyond their well-established glycosuric action [1].